BIOMAT Database Logo BIOMAT Database Logo

In vivo reversal of multidrug resistance by two new dihydropyridine derivatives, S16317 and S16324. 1994

L Kraus-Berthier, and N Guilbaud, and J L Peglion, and S Leonce, and A Lombet, and A Pierre, and G Atassi
Division de Cancérologie Expérimentale, Institut de Recherches Servier, Suresnes, France.

Two new dihydropyridine derivatives with low calcium channel affinity, S16317 and S16324, were found to fully overcome multidrug resistance in vitro. These two compounds increased doxorubicin cytotoxicity on the human COLO 320DM cell line and completely reversed the vincristine resistance of murine P388/VCR cells. In vivo, S16324 administered p.o. (200 mg/kg on days 1 to 4) or i.p. (50 mg/kg on days 1, 5, 9) in combination with vincristine (i.p.) restored the antitumor activity of vincristine in P388/VCR-bearing mice. S16317 showed a reversing activity when administered p.o., i.v. (days 1 to 4) or i.p. (days 1, 5, 9) at the same dose (25 mg/kg), suggesting a remarkable bioavailability. Moreover, these two compounds potentiated the antitumor activity of vincristine in the sensitive P388 leukemia, increasing the number of long-term survivors. These results suggest that combination chemotherapy using S16317 or S16324 would be effective not only in circumventing multidrug resistance but also in preventing the emergency of a population of resistant tumor cells in sensitive tumors.

UI MeSH Term Description Entries
D007941 Leukemia P388 An experimental lymphocytic leukemia originally induced in DBA/2 mice by painting with methylcholanthrene. P388D(1) Leukemia,P388, Leukemia
D008811 Mice, Inbred DBA An inbred strain of mouse. Specific substrains are used in a variety of areas of BIOMEDICAL RESEARCH such as DBA/1J, which is used as a model for RHEUMATOID ARTHRITIS. Mice, DBA,Mouse, DBA,Mouse, Inbred DBA,DBA Mice,DBA Mice, Inbred,DBA Mouse,DBA Mouse, Inbred,Inbred DBA Mice,Inbred DBA Mouse
D009368 Neoplasm Transplantation Experimental transplantation of neoplasms in laboratory animals for research purposes. Transplantation, Neoplasm,Neoplasm Transplantations,Transplantations, Neoplasm
D003110 Colonic Neoplasms Tumors or cancer of the COLON. Cancer of Colon,Colon Adenocarcinoma,Colon Cancer,Cancer of the Colon,Colon Neoplasms,Colonic Cancer,Neoplasms, Colonic,Adenocarcinoma, Colon,Adenocarcinomas, Colon,Cancer, Colon,Cancer, Colonic,Cancers, Colon,Cancers, Colonic,Colon Adenocarcinomas,Colon Cancers,Colon Neoplasm,Colonic Cancers,Colonic Neoplasm,Neoplasm, Colon,Neoplasm, Colonic,Neoplasms, Colon
D004095 Dihydropyridines Pyridine moieties which are partially saturated by the addition of two hydrogen atoms in any position.
D004317 Doxorubicin Antineoplastic antibiotic obtained from Streptomyces peucetius. It is a hydroxy derivative of DAUNORUBICIN. Adriamycin,Adriablastin,Adriablastine,Adriblastin,Adriblastina,Adriblastine,Adrimedac,DOXO-cell,Doxolem,Doxorubicin Hexal,Doxorubicin Hydrochloride,Doxorubicin NC,Doxorubicina Ferrer Farm,Doxorubicina Funk,Doxorubicina Tedec,Doxorubicine Baxter,Doxotec,Farmiblastina,Myocet,Onkodox,Ribodoxo,Rubex,Urokit Doxo-cell,DOXO cell,Hydrochloride, Doxorubicin,Urokit Doxo cell
D004354 Drug Screening Assays, Antitumor Methods of investigating the effectiveness of anticancer cytotoxic drugs and biologic inhibitors. These include in vitro cell-kill models and cytostatic dye exclusion tests as well as in vivo measurement of tumor growth parameters in laboratory animals. Anticancer Drug Sensitivity Tests,Antitumor Drug Screens,Cancer Drug Tests,Drug Screening Tests, Tumor-Specific,Dye Exclusion Assays, Antitumor,Anti-Cancer Drug Screens,Antitumor Drug Screening Assays,Tumor-Specific Drug Screening Tests,Anti Cancer Drug Screens,Anti-Cancer Drug Screen,Antitumor Drug Screen,Cancer Drug Test,Drug Screen, Anti-Cancer,Drug Screen, Antitumor,Drug Screening Tests, Tumor Specific,Drug Screens, Anti-Cancer,Drug Screens, Antitumor,Drug Test, Cancer,Drug Tests, Cancer,Screen, Anti-Cancer Drug,Screen, Antitumor Drug,Screens, Anti-Cancer Drug,Screens, Antitumor Drug,Test, Cancer Drug,Tests, Cancer Drug,Tumor Specific Drug Screening Tests
D004357 Drug Synergism The action of a drug in promoting or enhancing the effectiveness of another drug. Drug Potentiation,Drug Augmentation,Augmentation, Drug,Augmentations, Drug,Drug Augmentations,Drug Potentiations,Drug Synergisms,Potentiation, Drug,Potentiations, Drug,Synergism, Drug,Synergisms, Drug
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man

Related Publications

L Kraus-Berthier, and N Guilbaud, and J L Peglion, and S Leonce, and A Lombet, and A Pierre, and G Atassi
Reversal of multidrug resistance by two novel indole derivatives.
September 1992, Cancer research,
L Kraus-Berthier, and N Guilbaud, and J L Peglion, and S Leonce, and A Lombet, and A Pierre, and G Atassi
Reversal of P-glycoprotein associated multidrug resistance by new isoprenoid derivatives.
January 2001, Anti-cancer drug design,
L Kraus-Berthier, and N Guilbaud, and J L Peglion, and S Leonce, and A Lombet, and A Pierre, and G Atassi
Reversal of multidrug resistance by derivatives of acrivastine.
January 1997, Oncology reports,
L Kraus-Berthier, and N Guilbaud, and J L Peglion, and S Leonce, and A Lombet, and A Pierre, and G Atassi
Antimicrobial, anticoagulant, and cytotoxic evaluation of multidrug resistance of new 1,4-dihydropyridine derivatives.
September 2018, Saudi journal of biological sciences,
L Kraus-Berthier, and N Guilbaud, and J L Peglion, and S Leonce, and A Lombet, and A Pierre, and G Atassi
Reversal of multidrug resistance in murine lymphoma cells by amphiphilic dihydropyridine antioxidant derivative.
October 2010, Anticancer research,
L Kraus-Berthier, and N Guilbaud, and J L Peglion, and S Leonce, and A Lombet, and A Pierre, and G Atassi
New multidrug resistance reversal agents.
January 2003, Current drug targets,
L Kraus-Berthier, and N Guilbaud, and J L Peglion, and S Leonce, and A Lombet, and A Pierre, and G Atassi
Reversal of P-glycoprotein mediated multidrug resistance by novel anthranilamide derivatives.
February 1999, Bioorganic & medicinal chemistry letters,
L Kraus-Berthier, and N Guilbaud, and J L Peglion, and S Leonce, and A Lombet, and A Pierre, and G Atassi
Reversal by two dihydropyridine compounds of resistance to multiple anticancer agents in mouse P388 leukemia in vivo and in vitro.
October 1990, Japanese journal of cancer research : Gann,
L Kraus-Berthier, and N Guilbaud, and J L Peglion, and S Leonce, and A Lombet, and A Pierre, and G Atassi
Reversal of multidrug resistance in vitro and in vivo by 5-N-formylardeemin, a new ardeemin derivative.
August 2014, Apoptosis : an international journal on programmed cell death,
L Kraus-Berthier, and N Guilbaud, and J L Peglion, and S Leonce, and A Lombet, and A Pierre, and G Atassi
Pharmacokinetics and bioavailability of a newly synthesized dihydropyridine compound with multidrug resistance reversal activity.
October 2005, Biopharmaceutics & drug disposition,
Copied contents to your clipboard!